![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Diosynth Bv Oss Nl, based in United Kingdom, is a pharmaceutical company that stands out with its certifications from EDQM.
One of their significant offerings is Midazolam, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 1998-114 - Rev 01
This Chemical Type CEP, issued on April 12, 2002, remains in force until January 12, 2005, ensuring its reliability within the pharmaceutical industry.
Substance Number 936 associated with this CEP further emphasizes